Andelyn Biosciences has partnered with Queen's University to develop and manufacture a gene therapy candidate, AAV9-GM2, for the treatment of GM2 gangliosidoses using its Curator® Platform.
Key takeaway
Andelyn Biosciences partners with Queen's University for gene therapy development.
- Step 1 · The triggerAndelyn Biosciences partners with Queen's University to develop AAV9-GM2 gene therapy.
- Step 2 · Knock-onAndelyn enhances its manufacturing capabilities and reputation in gene therapy.
- Step 3 · Reaches youQueen's University advances its research capabilities leveraging Andelyn's expertise.
The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.
Source: PR Newswire
See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for your businessThis is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.